Managing Toxicity in Later-Line HER2+ mBC Treatments: Real-World Insights and Mitigation Strategies for Optimal Patient QOLs

Opinion
Video

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on the Cleopatra regimen with taxane, Trastuzumab, and Pertuzumab, and 11 months on Tdxd. As her disease is now progressing, so she needs 3rd line treatment. But despite some fatigue, she remains active with work and Yoga and her brain, MRIs are clear.

Video content above is prompted by the following:

  • Please explore key clinical trial data findings, emphasizing perspectives around clinical safety and efficacy.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
Photo of a man wearing a suit with a blue tie in front of a dark blue background
4 experts in this video
4 experts in this video
Photo of a man wearing glasses and a suit in front of a blue background
Related Content
Graphic of a person with a breast tumor

Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine

Bridget Hoyt
July 16th 2025
Article

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.

graphic of a breast with a tumor

KN026/KN046 Combo Yields Durable Responses in HER2+ mBC

Jax DiEugenio
July 7th 2025
Article

KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.

Graphic of a breast with tumors

Gedatolisib Combos Show Early Activity in mCRPC, Metastatic Breast Cancer

Tim Cortese
July 3rd 2025
Article

Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.

Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
June 30th 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Anatomical graphic of a person with a tumor in their left breast

First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC

Russ Conroy
June 4th 2025
Article

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

Graphic of a breast with a tumor.

Q&A: Strong Treatment Choices Can Build Trust in Patients With ESR1+ mBC

Bridget Hoyt
May 22nd 2025
Article

Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.